Annual report on surveillance of adverse events following immunisation in Australia, 2006
DOI:
https://doi.org/10.33321/cdi.2007.31.27Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccine safetyAbstract
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Adverse Drug Reactions Advisory Committee for 2006, and describes reporting trends over the seven-year period 2000 to 2006. There were 779 AEFI records for vaccines administered in 2006. This is an annual AEFI reporting rate of 3.8 per 100,000 population, the lowest since 2002 and a 10% decrease compared with 2005 (869 AEFI records; 4.3 records per 100,000 population). Dose-based AEFI reporting rates in 2006 were 1.9 per 100,000 doses of influenza vaccine for adults aged ≥18 years, 19.1 per 100,000 doses of pneumococcal polysaccharide vaccine for those aged ≥65 years and 12.5 per 100,000 doses of scheduled vaccines for children aged <7 years. Trend data showed transient increases in reporting of AEFI following the introduction of DTPa-IPV combination vaccines in November 2005 for children aged <7 years. The majority of the 779 AEFI records for 2006 described non-serious events while 11% (n=85) described AEFIs defined as serious. There was one report of death temporally associated with receipt of dTpa-IPV and typhoid vaccines in an adult with a history of a chronic medical condition. The most frequently reported individual AEFI was injection site reaction in children following a fourth or fifth dose of acellular pertussis-containing vaccine (70 reports per 100,000 doses). The data confirm the low rate of AEFI reported in Australia and demonstrate the ability of the system to detect and investigate signals such as those associated with changes in immunisation programs. Commun Dis Intell 2007;31:269–282.
Downloads
References
Mansoor O, Shin S, Maher C, and the Immunization Focus of WPRO. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: World Health Organization Regional Office for the Western Pacific; 1999.
Duclos P. A global perspective on vaccine safety. Vaccine 2004;22:2059–2063.
Chen RT, Destefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. Infect Dis Clin North Am 2001;15:21–39.
National Health and Medical Research Council. The Australian Immunisation Handbook, 8th edition. Canberra: Australian Government Publishing Service, 2003.
Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Available from: http://www.who-umc.org Accessed September 2007.
Lawrence GL, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia 2000–2002. Commun Dis Intell 2003;27:307–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 2004;28:324–338.
Lawrence G, Boyd I. Adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Commun Dis Intell 2004;28:490-492.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. [published erratum in Commun Dis Intell 2005;29:416] Commun Dis Intell 2005;29:248–262.
Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation for children aged less than 7 years in Australia, 1 January to 30 June 2005. Commun Dis Intell 2005;29:413–416.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006;30:319–333.
Lawrence GL, Boyd I. Supplementary report: surveillance of adverse events following immunisation for children aged less than 7 years in Australia, 1 January to 30 June 2006. Commun Dis Intell 2006;30:438–442.
Australian Government Department of Health and Ageing. Immunisation programs and initiatives. Available from: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/programs Accessed August 2007.
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. [published erratum in MMWR Morb Mortal Wkly Rep 2003;52:113.] MMWR Surveill Summ 2003;52 SS–1:1–28.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999;20:109–117.
The SAS system for Windows [computer program]. Version 9.1.3. Cary, NC: SAS Institute Inc.; 2005.
Australian Government Department of Health and Ageing. Additional reports – Childhood immunisation coverage. Commun Dis Intell 2007;31:333–334.
Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287–294.
Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in pre-term infants following DTPa and Hib immunization: a prospective study. J Paediatr Child Health 1997;33:418–421.
Schulzke S, Heininger U, Lucking-Famira M, Fahenstich H. Apnoea and bradycardia in preterm infants following immunisation with pentavalent and hexavalent vaccines. Eur J Pediatr 2005; 164:432–435.
Faldella G, Galletti S, Corvaglia L, Ancora G, Alessandroni R. Safety of DTaP-IPV-Hib-HBV hexavalent vaccine in very premature infants. Vaccine 2007;25:1036–1042.
Wise R, Iskander J, Pratt R, Campbell S, Ball R, Pless R, et al. Post licensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004;292:1702–1710.
Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. [published erratum in JAMA 2000;284:3129.] JAMA 2000;284:1271–1279.
Von Kries R, Toschle AM, Strassburger K, Kundi M, Kalies H, Nennsteil U, et al. Sudden and unexpected deaths after administration of hexavalent vaccines (DTPa-IPV-HBV-Hib): is there a signal? Eur J Pediatr 2005;164:61–69.
Zinka B, Rauch E, Buettner A, Penning R, Rueff F. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 2006;24:5779–5780.
Vennemann MMT, Butterfass-Bahloul T, Jorch G, Brinkmann B, Findeisen M, Sauerland C, et al. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 2007;25:336–340.
Global Advisory Committee on Vaccine Safety. Safety of hexavalent vaccines. Wkly Epidemiol Rec 2005;28:245–246. Available from: http://www.who.int/vaccine_safety/reports/June_2005/en/index.html Accessed August 2007.
Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105:e12.
Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003;179:191–194.
Jackson L, Benson P, Sneller V-P, Butler J, Thompson RS, Chen RT, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243–248.
Jackson L, Nelson J, Whitney C, Neuzil K, Benson P, Malais D, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006;24;151–156.
Brotherton J, Wang H, Schaffer, A, Quinn H, Menzies R, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell 2007;31 Suppl:i–S152.
Owen R, Roche PW, Yohannes K, Hope K, Yohannes K, Roberts A, et al. Australia's notifiable diseases status, 2005: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2007;31:1–70.
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2006. Commun Dis Intell 2007;31:185–121.
Roche P, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell 2007;31:86–100.
Downloads
Published
How to Cite
License
Copyright (c) 2007 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
